Skip to Content

Amoxicillin Dosage

Applies to the following strength(s): 250 mg ; 500 mg ; 125 mg/5 mL ; 50 mg/mL ; 250 mg/5 mL ; 125 mg ; 200 mg ; 400 mg ; 875 mg ; 200 mg/5 mL ; 400 mg/5 mL ; 600 mg ; 775 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Bacterial Endocarditis Prophylaxis

American Heart Association (AHA) recommendations:
-Immediate-release: 2 g orally as a single dose 30 to 60 minutes prior to procedure

Comments:
-Prophylaxis should be used for patients at high risk of adverse outcomes from endocarditis with underlying cardiac conditions who undergo any dental procedure that involves manipulation of gingival tissue or periapical region of a tooth and for those procedures that perforate oral mucosa.
-Prophylaxis should also be used for patients at high risk of adverse outcomes from endocarditis who undergo invasive respiratory tract procedures.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Chlamydia Infection

US CDC recommendations: 500 mg orally 3 times a day for 7 days in pregnant patients as an alternative to azithromycin

Comments:
-Women less than 25 years and those at an increased risk for chlamydia should be re-screened during the third trimester of pregnancy to prevent maternal postnatal complications and chlamydial infection in the infant.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Helicobacter pylori Infection

Immediate-release:
-Dual Therapy: 1 g orally every 8 hours for 14 days in combination with lansoprazole
-Triple Therapy: 1 g orally every 12 hours for 14 days in combination with clarithromycin and lansoprazole

Comments: Refer to clarithromycin and lansoprazole for full prescribing information.

Usual Adult Dose for Lyme Disease - Arthritis

Infectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 days

Comments:
-Duration of treatment depends upon severity of condition being treated.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Lyme Disease - Carditis

Infectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 days

Comments:
-Duration of treatment depends upon severity of condition being treated.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Lyme Disease - Erythema Chronicum Migrans

Infectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 days

Comments:
-Duration of treatment depends upon severity of condition being treated.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Lyme Disease

Infectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 days

Comments:
-Duration of treatment depends upon severity of condition being treated.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Pneumonia

Immediate-release:
-Mild, moderate, or severe infection: 500 mg orally every 8 hours or 875 mg every 12 hours

Use: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

IDSA and American Thoracic Society (ATS) recommendations:
Pneumonia:
-Immediate-release: 1 g orally 3 times a day

Comments:
-Patients should be treated for a minimum of 5 days, be afebrile for 48 to 72 hours, and have no more than 1 community-acquired pneumonia (CAP)-associated sign of clinical instability before discontinuing therapy.
-Used in combination with other medications.
-Current guidelines should be consulted for additional information.

Use: For outpatient empirical treatment of community-acquired pneumonia

Usual Adult Dose for Bronchitis

Immediate-release:
-Mild, moderate, or severe infection: 500 mg orally every 8 hours or 875 mg every 12 hours

Use: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

IDSA and American Thoracic Society (ATS) recommendations:
Pneumonia:
-Immediate-release: 1 g orally 3 times a day

Comments:
-Patients should be treated for a minimum of 5 days, be afebrile for 48 to 72 hours, and have no more than 1 community-acquired pneumonia (CAP)-associated sign of clinical instability before discontinuing therapy.
-Used in combination with other medications.
-Current guidelines should be consulted for additional information.

Use: For outpatient empirical treatment of community-acquired pneumonia

Usual Adult Dose for Sinusitis

Immediate-release:
-Mild to moderate infection: 250 mg orally every 8 hours or 500 mg every 12 hours
-Severe infection: 500 mg orally every 8 hours or 875 mg every 12 hours

Comments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.

Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

Usual Adult Dose for Urinary Tract Infection

Immediate-release:
-Mild to moderate infection: 250 mg orally every 8 hours or 500 mg every 12 hours
-Severe infection: 500 mg orally every 8 hours or 875 mg every 12 hours

Comments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.

Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

Usual Adult Dose for Tonsillitis/Pharyngitis

Extended-release: 775 mg orally once a day within 1 hour after a meal for 10 days

Comments: The full 10-day course of treatment should be completed in order to be effective.

Uses: For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes

IDSA recommendations:
Immediate-release: 1000 mg orally once a day or 500 mg orally twice a day

Use: For the treatment of Group A Streptococcal pharyngitis

Usual Adult Dose for Skin and Structure Infection

Immediate-release:
-Mild to moderate infection: 250 mg orally every 8 hours or 500 mg every 12 hours
-Severe infection: 500 mg orally every 8 hours or 875 mg every 12 hours

Comments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.

Use: For the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

IDSA recommendations:
-Immediate-release: 500 mg orally 3 times a day for 7 to 10 days

Use: For the treatment of erysipeloid

Usual Adult Dose for Cutaneous Bacillus anthracis

US CDC Recommendations: 1 g orally every 8 hours
Duration of prophylaxis: 60 days

Comments:
-Recommended as an alternative oral regimen for postexposure prophylaxis and cutaneous anthrax without systemic involvement; recommended for penicillin-susceptible strains
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Anthrax Prophylaxis

US CDC Recommendations: 1 g orally every 8 hours
Duration of prophylaxis: 60 days

Comments:
-Recommended as an alternative oral regimen for postexposure prophylaxis and cutaneous anthrax without systemic involvement; recommended for penicillin-susceptible strains
-Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Bacterial Endocarditis Prophylaxis

AHA recommendations:
Children:
-Immediate-release: 50 mg/kg orally as a single dose 30 to 60 minutes prior to procedure; maximum of 2 g/dose

Comments:
-Prophylaxis should be used for patients at high risk of adverse outcomes from endocarditis with underlying cardiac conditions who undergo any dental procedure that involves manipulation of gingival tissue or periapical region of a tooth and for those procedures that perforate oral mucosa.
-Prophylaxis should also be used for patients at high risk of adverse outcomes from endocarditis who undergo invasive respiratory tract procedures.
-Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Sinusitis

Immediate-Release Formulations:
Mild, Moderate, or Severe Infection:
3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours

Comments:
-Treatment should be continued for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic or evidence of bacterial eradication occurs.
-At least 10 days of treatment for any infection caused by Streptococcus pyogenes is recommended to prevent the occurrence of acute rheumatic fever.

Immediate-Release Formulations:
Mild to Moderate Infection:
4 months or older:
-Less than 40 kg: 20 mg/kg/day orally in divided doses every 8 hours or 25 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 250 mg orally every 8 hours or 500 mg every 12 hours

Severe Infection:
4 months or older:
-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hours

Comments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.

Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

Usual Pediatric Dose for Skin or Soft Tissue Infection

Immediate-Release Formulations:
Mild, Moderate, or Severe Infection:
3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours

Comments:
-Treatment should be continued for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic or evidence of bacterial eradication occurs.
-At least 10 days of treatment for any infection caused by Streptococcus pyogenes is recommended to prevent the occurrence of acute rheumatic fever.

Immediate-Release Formulations:
Mild to Moderate Infection:
4 months or older:
-Less than 40 kg: 20 mg/kg/day orally in divided doses every 8 hours or 25 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 250 mg orally every 8 hours or 500 mg every 12 hours

Severe Infection:
4 months or older:
-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hours

Comments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.

Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

Usual Pediatric Dose for Urinary Tract Infection

Immediate-Release Formulations:
Mild, Moderate, or Severe Infection:
3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours

Comments:
-Treatment should be continued for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic or evidence of bacterial eradication occurs.
-At least 10 days of treatment for any infection caused by Streptococcus pyogenes is recommended to prevent the occurrence of acute rheumatic fever.

Immediate-Release Formulations:
Mild to Moderate Infection:
4 months or older:
-Less than 40 kg: 20 mg/kg/day orally in divided doses every 8 hours or 25 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 250 mg orally every 8 hours or 500 mg every 12 hours

Severe Infection:
4 months or older:
-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hours

Comments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.

Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

Usual Pediatric Dose for Pneumonia

Immediate-Release Formulations:
Mild, Moderate, or Severe infection:
3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours
4 months or older:
-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hours

Use: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

IDSA and the Pediatric Infectious Diseases Society recommendations:
Immediate-release formulations:
4 months or older:
-Empiric therapy for presumed bacterial pneumonia: 90 mg/kg/day orally in 2 divided doses; maximum 4 g/day
-Streptococcus pneumoniae (penicillin minimum inhibitory concentration of 2 mcg/mL or less): 90 mg/kg/day orally in 2 divided doses or 45 mg/kg/day in 3 divided doses
-Group A Streptococcus: 50 to 75 mg/kg/day orally in 2 divided doses
-Haemophilus influenza typeable (A to F) or nontypeable: 75 to 100 mg/kg/day orally in 3 divided doses

Comments: Current guidelines should be consulted for additional information.

Use: For the management of community-acquired pneumonia

Usual Pediatric Dose for Bronchitis

Immediate-Release Formulations:
Mild, Moderate, or Severe infection:
3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours
4 months or older:
-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hours

Use: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

IDSA and the Pediatric Infectious Diseases Society recommendations:
Immediate-release formulations:
4 months or older:
-Empiric therapy for presumed bacterial pneumonia: 90 mg/kg/day orally in 2 divided doses; maximum 4 g/day
-Streptococcus pneumoniae (penicillin minimum inhibitory concentration of 2 mcg/mL or less): 90 mg/kg/day orally in 2 divided doses or 45 mg/kg/day in 3 divided doses
-Group A Streptococcus: 50 to 75 mg/kg/day orally in 2 divided doses
-Haemophilus influenza typeable (A to F) or nontypeable: 75 to 100 mg/kg/day orally in 3 divided doses

Comments: Current guidelines should be consulted for additional information.

Use: For the management of community-acquired pneumonia

Usual Pediatric Dose for Tonsillitis/Pharyngitis

12 years or older:
-Extended-release: 775 mg orally once a day within 1 hour after a meal for 10 days

Comments: The full 10-day course of treatment should be completed in order to be effective.

Uses: For the treatment of tonsillitis and/or pharyngitis secondary to S pyogenes

IDSA recommendations:
Immediate-release: 50 mg/kg (maximum 1000 mg) orally once a day or 25 mg/kg (maximum 500 mg) twice a day

Use: For the treatment of Group A Streptococcal pharyngitis

Usual Pediatric Dose for Lyme Disease

IDSA recommendations:
Children:
-Immediate-release: 50 mg/kg/day orally in 3 divides doses for 14 to 28 days; maximum single dose of 500 mg

Comments:
-Duration of treatment depends upon severity of condition being treated.
-Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Otitis Media

American Academy of Pediatrics (AAP) and American Academy of Family Physicians (AAFP) recommendations:
-Immediate-release: 80 to 90 mg/kg/day orally in 2 divided doses; some experts recommend 90 mg/kg orally in 2 divided doses as initial therapy

Comments:
-Optimal duration of treatment uncertain; however, for young children and children with severe disease at any age, a 10 day course is recommended; children 6 years or older with mild or moderate disease should find a duration of 5 to 7 days appropriate.
-Current guidelines should be consulted for additional information.

Use: For the treatment of acute otitis media

Usual Pediatric Dose for Inhalation Bacillus anthracis

AAP Recommendations:
Up to 1 week of age:
-Gestational age 32 to 37 weeks: 50 mg/kg orally in divided doses every 12 hours
-Term neonate: 75 mg/kg orally in divided doses every 8 hours

1 to 4 weeks:
-Gestational age 32 to 37 weeks: 75 mg/kg orally in divided doses every 8 hours
-Term neonate: 75 mg/kg/day orally in divided doses every 8 hours

1 month or older: 75 mg/kg/day orally in divided doses every 8 hours; not to exceed 1 g/dose

Duration of Therapy:
Postexposure prophylaxis for B anthracis infection: 60 days after exposure

Cutaneous anthrax without systemic involvement:
-Bioterrorism-related cases: To complete an antimicrobial regimen of up to 60 days from onset of illness
-Naturally-acquired cases: 7 to 10 days

Follow-up for severe anthrax:
-To complete a regimen of 10 to 14 days or longer (up to 4 weeks of age) or to complete a regimen of 14 days or longer (1 month or older)
-Patients may require prophylaxis to complete an antimicrobial regimen of up to 60 days from onset of illness.

Comments:
-Recommended as an alternative regimen for postexposure prophylaxis, the treatment of cutaneous anthrax without systemic involvement, and oral follow-up therapy for severe anthrax
-Recommended as an alternative for penicillin-susceptible strains
-Recommended for use with a protein synthesis inhibitor when used for follow-up therapy for severe anthrax (includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck).
-Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Cutaneous Bacillus anthracis

AAP Recommendations:
Up to 1 week of age:
-Gestational age 32 to 37 weeks: 50 mg/kg orally in divided doses every 12 hours
-Term neonate: 75 mg/kg orally in divided doses every 8 hours

1 to 4 weeks:
-Gestational age 32 to 37 weeks: 75 mg/kg orally in divided doses every 8 hours
-Term neonate: 75 mg/kg/day orally in divided doses every 8 hours

1 month or older: 75 mg/kg/day orally in divided doses every 8 hours; not to exceed 1 g/dose

Duration of Therapy:
Postexposure prophylaxis for B anthracis infection: 60 days after exposure

Cutaneous anthrax without systemic involvement:
-Bioterrorism-related cases: To complete an antimicrobial regimen of up to 60 days from onset of illness
-Naturally-acquired cases: 7 to 10 days

Follow-up for severe anthrax:
-To complete a regimen of 10 to 14 days or longer (up to 4 weeks of age) or to complete a regimen of 14 days or longer (1 month or older)
-Patients may require prophylaxis to complete an antimicrobial regimen of up to 60 days from onset of illness.

Comments:
-Recommended as an alternative regimen for postexposure prophylaxis, the treatment of cutaneous anthrax without systemic involvement, and oral follow-up therapy for severe anthrax
-Recommended as an alternative for penicillin-susceptible strains
-Recommended for use with a protein synthesis inhibitor when used for follow-up therapy for severe anthrax (includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck).
-Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Anthrax Prophylaxis

AAP Recommendations:
Up to 1 week of age:
-Gestational age 32 to 37 weeks: 50 mg/kg orally in divided doses every 12 hours
-Term neonate: 75 mg/kg orally in divided doses every 8 hours

1 to 4 weeks:
-Gestational age 32 to 37 weeks: 75 mg/kg orally in divided doses every 8 hours
-Term neonate: 75 mg/kg/day orally in divided doses every 8 hours

1 month or older: 75 mg/kg/day orally in divided doses every 8 hours; not to exceed 1 g/dose

Duration of Therapy:
Postexposure prophylaxis for B anthracis infection: 60 days after exposure

Cutaneous anthrax without systemic involvement:
-Bioterrorism-related cases: To complete an antimicrobial regimen of up to 60 days from onset of illness
-Naturally-acquired cases: 7 to 10 days

Follow-up for severe anthrax:
-To complete a regimen of 10 to 14 days or longer (up to 4 weeks of age) or to complete a regimen of 14 days or longer (1 month or older)
-Patients may require prophylaxis to complete an antimicrobial regimen of up to 60 days from onset of illness.

Comments:
-Recommended as an alternative regimen for postexposure prophylaxis, the treatment of cutaneous anthrax without systemic involvement, and oral follow-up therapy for severe anthrax
-Recommended as an alternative for penicillin-susceptible strains
-Recommended for use with a protein synthesis inhibitor when used for follow-up therapy for severe anthrax (includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck).
-Current guidelines should be consulted for additional information.

Renal Dose Adjustments

Extended-release Tablets:
-Severe renal dysfunction (CrCl less than 30 mL/min): Not recommended.

Immediate-release formulations:
Mild to moderate renal dysfunction: No adjustment recommended.
Severe renal dysfunction:
-GFR 10 to 30 mL/min: 250 or 500 mg orally every 12 hours, depending on severity of infection
-GFR less than 10 mL/min: 250 or 500 mg orally every 24 hours, depending on severity of infection

Comments: Patients with severe renal dysfunction (CrCl less than 30 mL/min) should not receive the 875 mg tablets.

Liver Dose Adjustments

Data not available

Precautions

Extended-release tablets: Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

Dialysis

Hemodialysis:
-Extended-release Tablets: Not recommended.
-Immediate-release: 250 or 500 mg orally every 24 hours, depending on severity of infection; patients should receive an additional dose both during and at the end of dialysis

Other Comments

Administration advice:
-Extended-release tablets: Do not crush or chew; take with food.
-Oral suspension: Shake well before use; after reconstitution, the required amount of suspension should be placed directly on patient's tongue and swallowed; alternatively, may add to milk, fruit juice, water, ginger ale, or cold drinks and taken immediately.

Storage requirements:
-Dispense in a tight container.
-Oral suspension: Keep bottle tightly closed; refrigeration preferable but not required; discard after 14 days.

Reconstitution/preparation techniques:
-Oral suspension: The manufacturer product information should be consulted.

General:
-To reduce the development of drug-resistant bacteria and maintain efficacy, this drug should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
-When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy; in absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Patient advice:
-Seek medical attention immediately if an allergic reaction occurs.
-Contact your healthcare provider if watery and bloody stools develop.
-The full course of therapy should be completed.

Hide